Conceptualizing Cancer Drugs as Classifiers
نویسندگان
چکیده
منابع مشابه
Conceptualizing Cancer Drugs as Classifiers
Cancer and healthy cells have distinct distributions of molecular properties and thus respond differently to drugs. Cancer drugs ideally kill cancer cells while limiting harm to healthy cells. However, the inherent variance among cells in both cancer and healthy cell populations increases the difficulty of selective drug action. Here we formalize a classification framework based on the idea tha...
متن کاملConceptualizing overdiagnosis in cancer screening.
The aim of cancer screening is to detect asymptomatic cancers whose treatment will result in extension of life, relative to length of life absent screening. Unfortunately, cancer screening also results in overdiagnosis, the detection of cancers that, in the absence of screening, would not present symptomatically during one's lifetime. Thus, their detection and subsequent treatment is unnecessar...
متن کاملConceptualizing Adjectives Conceptualizing Adjectives Conceptualizing Adjectives
We specify a model for the conceptual interpretation of relative adjectives (like \big"), which covers a crucial aspect of the underlying comprehension process { the comparison to a norm that is associated with a comparison class. Building on an elaborate domain ontology and knowledge about intercorrelations, comparison classes are dynamically created depending on the context in which adjectiva...
متن کاملNatural moieties as promising anti - cancer drugs
There have been a variety of chemical drugs that are being synthesized for cancer treatment. Besides the development of number of therapeutic drugs, cancer is still one of the leading cause for mortality worldwide. One associated reason for high rate of mortality in cancer, is side effects of the existing drug therapy. However recent inventions using natural metabolites have demonstrated the lo...
متن کاملThe future of antibodies as cancer drugs.
Targeted therapeutics such as monoclonal antibodies (mAbs) have proven successful as cancer drugs. To profile products that could be marketed in the future, we examined the current commercial clinical pipeline of mAb candidates for cancer. Our analysis revealed trends toward development of a variety of noncanonical mAbs, including antibody-drug conjugates (ADCs), bispecific antibodies, engineer...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: PLoS ONE
سال: 2014
ISSN: 1932-6203
DOI: 10.1371/journal.pone.0106444